Damora Therapeutics, Inc.
DMRA
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue
N/A
Net Income (TTM)
-$292M
▼ -878.8% YoY
Op. Margin
–
ROIC
-54.49%
▼ -57.4pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$59M
▲ +63.9% YoY
Op. Cash Flow (TTM)
-$59M
▲ +63.9% YoY
Net Debt
-$527M
Net Cash Position
Cash & Equiv.
$528M
Continue Research
Peers
Pharmaceutical Preparations · Pick stocks to compare with DMRA
Held by ETFs
DMRA is in 23 US ETFs. The largest of them, with DMRA's weight in each:
Damora Therapeutics (DMRA) in two numbers
Questions about Damora Therapeutics
Is Damora Therapeutics (DMRA) overvalued?
Damora Therapeutics trades at 2.56 times earnings. Intrinsiqq's fair value calculator has no opening value for DMRA, so weigh those multiples against the company's own history and the peers above. See how to tell if a stock is overvalued.
Does Damora Therapeutics (DMRA) pay a dividend?
No. Damora Therapeutics (DMRA) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.
Source: 10-Q filed 2 Nov 2026 (period ending 30 Sept 2026), SEC. Price: last close 10 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong? Check it in DMRA's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing DMRA
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.